Další formáty:
BibTeX
LaTeX
RIS
@article{2247017, author = {Juřica, Jan and Goněc, Roman and Bártová, Adéla and Gregorová, Jana}, article_location = {Warsaw}, article_number = {s1}, doi = {http://dx.doi.org/10.2478/afpuc-2022-0006}, keywords = {Immune checkpoint inhibitors; immunotherapy; adverse effect; autoimmunity}, language = {cze}, issn = {2453-6725}, journal = {European Pharmaceutical Journal}, title = {Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience}, url = {https://sciendo.com/es/article/10.2478/afpuc-2022-0006}, volume = {69}, year = {2022} }
TY - JOUR ID - 2247017 AU - Juřica, Jan - Goněc, Roman - Bártová, Adéla - Gregorová, Jana PY - 2022 TI - Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience JF - European Pharmaceutical Journal VL - 69 IS - s1 SP - 84-86 EP - 84-86 PB - Sciendo SN - 24536725 KW - Immune checkpoint inhibitors KW - immunotherapy KW - adverse effect KW - autoimmunity UR - https://sciendo.com/es/article/10.2478/afpuc-2022-0006 N2 - Autoimmune adverse effects of immune checkpoint inhibitors (ICIs) are rare but may be life-threatening. We performed a retrospective analysis of the immune-related adverse effects (irAEs) of ICIs in the Masaryk Memorial Cancer Institute (MMCI) from 2011 to 2021. The ICIs were administered to 648 patients. Severe irAEs were pronounced in 83 patients (12.8%). Further, we report a case of severe irAE after treatment with ipilimumab and nivolumab. Prednisone, mesalazine, octreotide, infliximab, vedolizumab, and mycophenolate mofetil were used to manage G4 colitis, with partial response. Early diagnosis and appropriate management of irAE are essential in the perspective of further oncological treatment. ER -
JUŘICA, Jan, Roman GONĚC, Adéla BÁRTOVÁ a Jana GREGOROVÁ. Immune-Mediated Adverse Effects of Checkpoint Inhibitors: A Clinical Experience. \textit{European Pharmaceutical Journal}. Warsaw: Sciendo, 2022, roč.~69, s1, s.~84-86. ISSN~2453-6725. Dostupné z: https://dx.doi.org/10.2478/afpuc-2022-0006.
|